Physician profile
Tedd March
NPI 1639746563
$585.83
in general payments reported to CMS, 2019-2025
11 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $146 · 2024: $117 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $158.26 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $114.21 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $110.88 | 2023 | |
| Pfizer INC. | $45.04 | 2024-2025 | |
| Vertex Pharmaceuticals Incorporated | $32.31 | 2025 | |
| Mylan Specialty L.P. | $31.93 | 2024 | Yupelri |
| Viatris Specialty LLC | $28.87 | 2025 | Yupelri |
| Bioventus LLC | $20.83 | 2023 | Gelsyn-3 |
| Sumitomo Pharma America, INC. | $15.14 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $14.36 | 2024 | Farxiga |
| Si-Bone, INC. | $14.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tedd March listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.